Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Share:
Related EW
Oppenheimer: 3 Healthcare Stocks And 2 Energy Stocks To Buy Now
CRT Reiterates On Edwards Lifesciences, Sees 'Many Future Growth Opportunities'

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

DateFirmActionFromTo
Apr 2015BarclaysMaintainsEqual-weight
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Bank of AmericaMaintainsNeutral

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...

Get Benzinga's Newsletters